Specialist healthcare group BTG revealed on Tuesday that it will take a one-off charge after disappointing results from its 'CytoFab' study meant that further development of the drug has been halted.
The group has received top-line data from an AstraZeneca study comparing the efficacy and safety of AZD9773 with a placebo. AZD9773, or CytoFab, is a developing treatment for severe sepsis and/or septic shock.
It showed that CytoFab "did not show any significant improvements versus placebo in respect of the primary endpoint, ventilator-free days, or secondary endpoints including mortality."
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
As such, AstraZeneca decided to halt any further development of CytoFab and will hand the asset back to BTG. However, BTG said that it doesn't expect to conduct any further development itself, meaning that it will take a charge of £28m in the current financial year, of which £25m relates to a non-cash impairment of intangible and tangible fixed assets.
"These results are obviously disappointing, as the treatment of severe sepsis remains a major unmet need. Our core business and trading continue on track, as described in our recent interim management statement," said BTG's Chief Executive Officer Louise Makin.
Nevertheless, analysts at Jefferies said that the Cyto failure is "unfortunately not surprising but largely priced-in".
"We highlighted this as an upcoming high-risk binary event in our July 11th downgrade to 'hold', as sepsis is a very challenging indication. Given the stock's 15-20% recent sell-off, we see minimal downside from current levels on today's setback."
BC
-
Reeves warned against property tax shake-up – 3 ways it could backfire on first-time buyersRachel Reeves reportedly has her eye on high-end property taxes in the upcoming Budget, but there are concerns a shake-up could unintentionally hamper those trying to get on the housing ladder
-
Average Brits want to retire five years before they can – who has the widest retirement gap?Brits are expecting to work for longer than ever but there are big disparities in the number of extra working years predicted. A small tweak could help close the gap
